Other grades of this product :
| Product Name: | YC-1 | | Synonyms: | 2-Furanmethanol, 5-[1-(phenylmethyl)-1H-indazol-3-yl]-;Nsc728165;(5-(1-Benzyl-1H-indazol-3-yl)furan-2-yl)Methanol;YC 1 (pharMaceutical);1-Benzyl-3-(5-hydroxymethylfur-2-yl)indazole;1-benzyl-3-(5-hydroxymethyl-furan-2-yl)indazole;Lificiguat(YC-1);5-[1-(PHENYLMETHYL)-1H-INDAZOL-3-YL]-2-FURANMETHANOL | | CAS: | 170632-47-0 | | MF: | C19H16N2O2 | | MW: | 304.34 | | EINECS: | | Product Categories: | | Mol File: | 170632-47-0.mol |
| Melting point | 110-112℃ | | Boiling point | 522.2±50.0 °C(Predicted) | | density | 1.24±0.1 g/cm3(Predicted) | | storage temp. | Sealed in dry,Room Temperature | | solubility | DMSO: 12 mg/mL | | pka | 13.83±0.10(Predicted) | | form | solid | | color | white | | Stability: | Stable for 2 years from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20° for up to 3 months. |
| Description | YC-1 (170632-47-0) is a nitric oxide-independent activator of soluble guanylyl cyclase (sGC). Significantly elevates cGMP levels and inhibits collagen-stimulated aggregation of rabbit platelets (IC50?= 14.6 μM).1?Induces human endometrial cancer cell senescence via modulation of HIF1α activity.2?Induces degradation of HIF1α.3?Protects against glutamate-induced neuronal damage4?and β-amyloid-induced toxicity in differentiated PC12 cells5. | | Uses | YC-1 has been used as a hypoxia-inducible factor 1α (HIF-1α) inhibitor:- to reduce hypoxia induced Jagged1 expression in cardiomyocytes (CMs)
- to study its effect on progenitor expansion and CD34+ and side population (SP) cell phenotype and on the proliferation rate of cells with an ability to form long term colony forming units
- to study its effect on regulating sphingosine 1-phosphate (S1P) bound to albumin induced plasminogen activator inhibitor 1 (PAI-1) expression by activating Rho/ Rho-associated protein kinase (ROCK) pathway.
| | General Description | A nitric oxide-independent, superoxide-sensitive activator of soluble guanylyl cyclase. Inhibits platelet adhesion to collagen and acts as an antithrombotic agent. Reported to reduce HIF-1α levels and xenograft growth. | | Biochem/physiol Actions | YC-1 activates soluble guanylyl cyclase and prevents platelet aggregation and vascular contraction. It has a potential to treat circulation disorders. YC-1 also has an ability to inhibit hypoxia-inducible factor 1α (HIF-1α) activity in vitro. It acts as a potential antiangiogenic anticancer agent. | | References | 1) Martin?et al.?(2001),?YC-1 activation of human soluble guanylyl cyclase has both heme-dependent and heme-independent components;?Proc. Natl. Acad. Sci. USA,?98?12938
2) Kato?et al.?(2006),?Induction of human endometrial cancer cell senescence through modulation of HIF-1alpha activity by EGLN1; Int. J. Cancer,?118?1144
3) Kim?et al.?(2006),?A domain responsible for HIF-1alpha degradation by YC-1, a novel anticancer agent; Int. J. Oncol.,?29?255
4) Tai?et al. (2018),?Therapeutic window for YC-1 following glutamate-induced neuronal damage and transient focal cerebral ischemia; Mol. Med. Rep.,?17?6490
5) Tsai?et al.?(2013),?The role of heat shock protein 70 in the protective effect of YC-1 on β-amyloid-induced toxicity in differentiated PC12 cells.; PLoS One,?8(7)?e69320 |
| YC-1 Preparation Products And Raw materials |
|
日本语
한국어
Français
Deutsch
España
Türkiye